https://doi.org/10.55788/9521d0a1
The sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin has been shown safe and efficacious in patients with HFpEF in the EMPEROR-Preserved trial (NCT03057951) [1]. The current analysis, presented by Prof. Michael Böhm (University of the Saarland, Germany), investigated the efficacy of empagliflozin in the study population of this trial according to age. The EMPEROR-Preserved trial randomised 5,988 patients with heart failure and an ejection fraction of â„40% to either placebo or empagliflozin [2]. The primary outcome was a composite of cardiovascular death or hospitalisation for heart failure. For the current analysis, patients were stratified into 4 age groups: <65 years, 65â74 years, 75â79 years, and â„80 years.
After 52 weeks of treatment, no interaction effect was seen between age and the efficacy of empagliflozin on the primary outcome measure (Ptrend=0.33). The corresponding hazard ratios for participants in the empagliflozin arm were 0.83, 0.86, 0.72, and 0.73 (youngest to oldest age group). Additionally, kidney function as measured by eGFR slope was stable across the age groups in empagliflozin users (Ptrend =0.32), indicating that the protection of the kidney is not associated with age. Finally, participants on empagliflozin were less likely to deteriorate concerning quality-of-life, measured through the Kansas City Cardiomyopathy Questionnaire (KCCQ) â Clinical Summary Score, and this effect was independent of age.
- Anker SD, et al. N Engl J Med. 2021;385(16):1451â1461.
- Böhm M, et al. Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: Insights from the EMPEROR-Preserved Trial. ePosters â focus on Chronic Heart Failure 1, Heart Failure 2022, 21â24 May, Madrid, Spain.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« EMPULSE: Empagliflozin delivers rapid and clinically meaningful decongestion Next Article
DAPA-HF: Dapagliflozin is safe and efficacious in frail patients »
« EMPULSE: Empagliflozin delivers rapid and clinically meaningful decongestion Next Article
DAPA-HF: Dapagliflozin is safe and efficacious in frail patients »
Table of Contents: HFA 2022
Featured articles
Phase 3 and 4 Trials
GALACTIC-HF: Omecamtiv mecarbil as option for HFrEF patients with low SBP
HELIOS-A: Vutrisiran meets exploratory endpoints
Patiromer helps HFrEF patients to optimise RAAS inhibitors without hyperkalaemia
FIDELITY: Cardiorenal benefits of finerenone, regardless of LVH status
DAPA-VO2: Rapid effect of dapagliflozin on peak VO2 in stable HFrEF
Phase 1/2 Trials
Significant improvement in BP from istaroxime, a novel non-adrenergic agent
SERENADE: Macitentan fails in HFpEF plus PAH
Combination of filgrastim and dutogliptin appears safe in STEMI
Therapeutic Devices
Cardiac contractility modulation therapy promising for patients with HFpEF
REBALANCE-HF: Encouraging observations for splanchnic nerve ablation in HFpEF
Updates on SGLT2 Inhibitors
DAPA-HF: Dapagliflozin is safe and efficacious in frail patients
EMPEROR-Preserved: Empagliflozin stable across age groups
EMPULSE: Empagliflozin delivers rapid and clinically meaningful decongestion
Dapagliflozin performs consistently across LVEF in HF
Miscellaneous Topics
Cardiac wasting relevant for clinical outcomes in cancer
Urocortin-2 a potential treatment target for HFpEF
Should ATTR-CM be added to the differential diagnosis of patients with HF?
Delayed initiation of novel GDMTs associated with adverse outcomes in HF patients
Related Articles
September 27, 2021
SGLT2i or GLP-1-RA for heart protection in type 2 diabetes?
August 19, 2021
Proenkephalin: A useful biomarker for new-onset heart failure?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy